Insight Molecular Diagnostics (LTS:0KCC) Margin of Safety % (DCF Earnings Based): N/A (As of Jul. 13, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0KCC Insight Molecular Diagnostics Inc LTS:0KCC
52 GF Score
Price $5.03
GF Value $1.25
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Insight Molecular Diagnostics Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Insight Molecular Diagnostics's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

LTS:0KCC vs XGN, BDSX, BNR: Margin of Safety % (DCF Earnings Based) Comparison

For the Diagnostics & Research subindustry, Insight Molecular Diagnostics's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Insight Molecular Diagnostics Margin of Safety % (DCF Earnings Based) vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Insight Molecular Diagnostics's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Insight Molecular Diagnostics's Margin of Safety % (DCF Earnings Based) falls into.


LTS:0KCC
52GF Score
Insight Molecular Diagnostics Inc LTS:0KCC
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Insight Molecular Diagnostics (LTS:0KCC) Overvalued in 2026?

Based on GuruFocus' analysis, Insight Molecular Diagnostics stock appears to be overvalued. The current stock price of $5.03 is trading 302.4% above its estimated GF Value™ of $1.25. GuruFocus considers Insight Molecular Diagnostics to be Significantly Overvalued.

Key valuation signals for LTS:0KCC:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: $1.25 vs. price of $5.03 (302.4% above fair value)
  • GF Score™: 52/100 with 7 warning signs

No single metric tells the full story. See the LTS:0KCC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Insight Molecular Diagnostics Business Description

Other Exchanges IMDX:USA7OC0:Germany
Address 2 International Plaza Drive, Suite 510, Nashville, TN, USA, 37217
Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The Company's flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is also in the process of rebranding its RUO test kit, GraftAssure, as GraftAssureIQ, and rebranding its future in-vitro diagnostic (IVD) test kit as GraftAssureDx. The company geographically operates in the United States, the United Kingdom, Europe, and the Asia-Pacific regions, with maximum revenue generated from the USA.
52GF Score

Get the complete analysis for LTS:0KCC

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.03
Price
$1.25
GF Value